💊 الأدوية من أ إلى ي 🧬 الأهداف 🛠 الأدوات 📚 الأدلة
جميع الأدوية تصنيفات الأدوية المجالات العلاجية الآثار الجانبية
الأدلة المسرد الجدول الزمني
المقارنات مسارات الأدوية عائلات الأدوية
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Yttrium Chloride

CHEMBL5316164 Phase 4 معتمد Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
195.3 g/mol
LogP
—
Phase
4

Yttrium chloride is an inorganic yttrium salt that serves primarily as a precursor and starting material for the synthesis of radioactive yttrium-90 labeled radiopharmaceuticals used in radioimmunotherapy and targeted radionuclide therapy of lymphomas and other cancers. The stable yttrium chloride can be used in research applications and as a pharmaceutical intermediate. In oncology, yttrium chemistry underpins radiolabeled antibody conjugates used for lymphoma treatment.

الوزن الجزيئي

195,2600 g/mol

TPSA

0,00 Ų

المجالات العلاجية

Lymphoma Leukemia

آلية العمل

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

SMILES

[Cl-].[Cl-].[Cl-].[Y+3]

InChI

InChI=1S/3ClH.Y/h3*1H;/q;;;+3/p-3

Molecular Formula

Cl3Y

HBD / HBA

- / 3

الروابط القابلة للدوران

0

الذرات الثقيلة

4

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

Yttrium chloride is an inorganic yttrium salt that serves primarily as a precursor and starting material for the synthesis of radioactive yttrium-90 labeled radiopharmaceuticals used in radioimmunotherapy and targeted radionuclide therapy of lymphomas and other cancers. The stable yttrium chloride can be used in research applications and as a pharmaceutical intermediate. In oncology, yttrium chemistry underpins radiolabeled antibody conjugates used for lymphoma treatment.

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

Yes, Yttrium Chloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL5316164. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 10198055. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.